Immunome (NASDAQ:IMNM) Stock Price Up 5.3%

Immunome, Inc. (NASDAQ:IMNM) shares were up 5.3% on Tuesday . The stock traded as high as $25.42 and last traded at $25.26. Approximately 148,028 shares traded hands during trading, a decline of 78% from the average daily volume of 685,658 shares. The stock had previously closed at $24.00.

Analyst Upgrades and Downgrades

IMNM has been the subject of a number of analyst reports. Wedbush lifted their price objective on shares of Immunome from $12.00 to $19.00 and gave the company an “outperform” rating in a report on Tuesday, January 23rd. SVB Leerink began coverage on Immunome in a research note on Monday, January 29th. They set an “outperform” rating and a $30.00 price target for the company. Finally, Leerink Partnrs reissued an “outperform” rating on shares of Immunome in a report on Monday, January 29th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Immunome presently has an average rating of “Buy” and an average target price of $24.50.

Immunome Trading Down 3.3 %

The stock has a market capitalization of $1.35 billion, a PE ratio of -13.64 and a beta of 1.67. The stock’s fifty day simple moving average is $22.09 and its 200-day simple moving average is $13.40.

Institutional Investors Weigh In On Immunome

A number of institutional investors have recently added to or reduced their stakes in IMNM. Vanguard Group Inc. lifted its position in shares of Immunome by 339.0% during the 4th quarter. Vanguard Group Inc. now owns 1,740,026 shares of the company’s stock worth $18,618,000 after buying an additional 1,343,697 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in Immunome by 505.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,051,222 shares of the company’s stock worth $11,249,000 after purchasing an additional 877,592 shares during the last quarter. Barclays PLC purchased a new stake in shares of Immunome during the 4th quarter valued at $882,000. Royal Bank of Canada boosted its holdings in shares of Immunome by 3.2% in the 4th quarter. Royal Bank of Canada now owns 29,484 shares of the company’s stock worth $315,000 after buying an additional 928 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its position in Immunome by 25.0% during the fourth quarter. Point72 Asset Management L.P. now owns 682,619 shares of the company’s stock valued at $7,304,000 after buying an additional 136,700 shares during the period. 44.58% of the stock is owned by institutional investors.

Immunome Company Profile

Immunome, Inc operates as a biotechnology company that develops targeted cancer therapies. Its portfolio includes immunotherapies, targeted effectors, radioligand therapies, and antibody drug conjugates (ADCs). The company also offers rapid screening of novel antibodies and targets through memory B cell hybridoma technology.